Published online May 21, 2017. doi: 10.3748/wjg.v23.i19.3488
Peer-review started: January 3, 2017
First decision: February 10, 2017
Revised: February 25, 2017
Accepted: April 21, 2017
Article in press: April 21, 2017
Published online: May 21, 2017
Processing time: 141 Days and 23.1 Hours
To assess the relationship between serum levels of insulin-like growth factor-1 (IGF1)/IGF-binding protein-3 (IGFBP3) and the risk of esophageal carcinoma.
We assessed the relationship between the serum levels of these molecules and the risk of esophageal cancer in a prospective, nested case-control study of participants from the Japan Collaborative Cohort Study. A baseline survey was conducted from 1988 to 1990. Of the 110585 enrolled participants, 35% donated blood samples. Those who had been diagnosed with esophageal cancer were considered cases for nested case-control studies. A conditional logistic model was used to estimate odds ratios for the incidence of esophageal cancer associated with serum IGF1 and IGFBP3 levels.
Thirty-one cases and 86 controls were eligible for the present assessment. The molar ratio of IGF1/IGFBP3, which represents the free and active form of IGF1, was not correlated with the risk of esophageal carcinoma. A higher molar difference between IGFBP3 and IGF1, which estimates the free form of IGFBP3, was associated with a decreased risk of esophageal carcinoma (P = 0.0146), and people in the highest tertile had the lowest risk (OR = 0.107, 95%CI: 0.017-0.669). After adjustment for body mass index, tobacco use, and alcohol intake, the molar difference of IGFBP3-IGF1 was inversely correlated with the risk of esophageal carcinoma (P = 0.0150).
The free form of IGFBP3, which is estimated by this molar difference, may be inversely associated with esophageal cancer incidence.
Core tip: Insulin-like growth factor-1 (IGF1) is a potent mitogen, whereas IGF-binding protein-3 (IGFBP3) binds and inhibits IGF1. High circulating IGF1 and low IGFBP3 are associated with increased risk of several cancers. Here we assessed the relationship between these molecules and the risk of esophageal carcinoma in a prospective, nested case-control study from the Japan Collaborative Cohort Study. Free IGF1, represented by the molar ratio of IGF1/IGFBP3, was not correlated with the risk of esophageal carcinoma. The free form of IGFBP3, which is estimated by the molar difference of IGFBP3-IGF1, may be inversely associated with esophageal cancer incidence.
